Every material Form 8-K Sana Biotechnology, Inc. has filed with the SEC since August 10, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Sana Biotechnology reported third-quarter 2026 GAAP net income of $20.4 million, or $0.07 per share, compared with a net loss of $42.2 million, or $0.16 per share, a year earlier. The swing was mainly due to a $63.4 million non-cash gain from changes in the fair value of success payment and contingent consideration liabilities, while non-GAAP net loss widened to $43.0 million from $39.0 million, and cash, equivalents and marketable securities fell to $121.7 million with runway expected into mid-2027.
Q3 2026 GAAP net income was $20.4 million ($0.07 per share), versus a $42.2 million net loss in Q3 2025, including a $63.4 million non-cash gain.
Q3 2026 non-GAAP net loss was $43.0 million ($0.14 per share), compared with $39.0 million ($0.15 per share) in Q3 2025.
Cash, cash equivalents and marketable securities were $121.7 million at September 30, 2026, down from $138.4 million at December 31, 2025; cash used in operations was $108.9 million for the nine months.
Q3 2026 research and development expenses were $33.9 million, up from $30.1 million, and the company expects cash runway into mid-2027.
Sana Biotechnology furnished an updated corporate presentation under Regulation FD on September 8, 2026, which it plans to discuss at investor conferences. The filing contains no financial results, and it restates development goals, including a 2026 goal to file an IND for SC451 and start a Phase 1/2 trial, which matter to shareholders as timelines to watch.
The presentation is dated September 8, 2026 and is furnished as Exhibit 99.1; the filing reports no revenue, earnings or guidance.
The company's stated 2026 goal is to file an IND for SC451 and begin a Phase 1/2 trial in type 1 diabetes.
The presentation cites an earlier hypoimmune islet cell transplant in one patient (UP421), with C-peptide data through 14 months.
SG293 first-in-human data are potentially expected in the first half of 2027, and SG227 clinical study as early as 2027.
Sana Biotechnology reported second-quarter 2026 results with a net loss of $63.6 million, or $0.22 per share, compared with $93.8 million, or $0.39 per share, a year earlier; the prior-year figure included a $44.6 million impairment of long-lived assets. Cash, cash equivalents, and marketable securities were $160.5 million at June 30, 2026, and the company said its cash runway extends into mid-2027.
Q2 2026 net loss of $63.6 million ($0.22 per share) vs. $93.8 million ($0.39 per share) in Q2 2025; Q2 2025 included a $44.6 million impairment charge
Cash, cash equivalents, and marketable securities of $160.5 million at June 30, 2026, up from $138.4 million at December 31, 2025, after $93.3 million in net equity proceeds
Mayo Clinic made a $25.0 million equity investment in connection with a collaboration to advance SC451
Company expects to file an IND and begin a Phase 1/2 trial for SC451 and generate first-in-human SG293 data as early as this year
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Sana Biotechnology, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →